Arrowstreet Capital
ADMA icon

Arrowstreet Capital’s ADMA Biologics ADMA Stock Holding History

Arrowstreet Capital’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-360,565
Closed -$6.57M – 1834
2025
Q2 		$6.57M Sell
360,565
-755,494
-68% -$15.4M ﹤0.01% 1051
2025
Q1 		$22.1M Sell
1,116,059
-1,646,641
-60% -$28.5M 0.02% 570
2024
Q4 		$47.4M Buy
2,762,700
+1,013,456
+58% +$19.1M 0.04% 389
2024
Q3 		$35M Buy
1,749,244
+1,084,186
+163% +$16.9M 0.03% 409
2024
Q2 		$7.43M Buy
665,058
+599,100
+908% +$5.03M 0.01% 727
2024
Q1 		$435K Buy
+65,958
New +$361K ﹤0.01% 1468
2018
Q4 		– Sell
-16,400
Closed -$102K – 1325
2018
Q3 		$102K Sell
16,400
-7,700
-32% -$44.3K ﹤0.01% 1047
2018
Q2 		$108K Buy
+24,100
New +$120K ﹤0.01% 1032

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.82B AUM 73.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Arrowstreet Capital's ADMA Position: Q3 2025 in Review

Arrowstreet Capital sold out of ADMA Biologics (ADMA) in Q3 2025, closing a stake of 360,565 shares — an estimated $6.57M sold.

Arrowstreet Capital first reported a position in ADMA in Q2 2018 and held it in 8 quarters. The position peaked at $47.4M in Q4 2024. 365 funds tracked by Wall St. Rank hold ADMA as of Q3 2025.

  • Arrowstreet Capital reported no remaining ADMA Biologics position as of Q3 2025 after selling out during the quarter.
  • Arrowstreet Capital sold 360,565 ADMA Biologics shares in Q3 2025, an estimated $6.57M.
  • Arrowstreet Capital first reported a position in ADMA Biologics in Q2 2018 and held it in 8 quarters.
  • Arrowstreet Capital's ADMA Biologics position peaked at $47.4M in Q4 2024.
  • 365 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2025.

Based on Arrowstreet Capital's 13F filing for Q3 2025, filed 13 Nov 2025.